Skip to main content

Table 4 Response rates

From: Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

  Patients (n = 42)
Response (WHO criteria)  
Complete 3 (7.1%)
Partial 12 (28.6%)
   Overall  
   (Complete + Partial) 15 (35.7%)
Stable Disease 19 (45.2%)
Progressive Disease 6 (14.3%)
Missing data 2 (4.8%)